Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Download Data

Edgewise Therapeutics Inc Non-current Assets to Total Assets Ratio for the year ending December 31, 2023: 0.04

Edgewise Therapeutics Inc Non-current Assets to Total Assets Ratio is 0.04 for the year ending December 31, 2023, a -7.11% change year over year. The non-current assets to total assets ratio measures the proportion of a company's non-current assets to its total assets. It is calculated by dividing the total non-current assets by the total assets. This ratio provides insights into the composition of a company's asset base and the extent to which it relies on non-current assets, such as property, plant, and equipment, to generate revenue. A higher ratio suggests a greater proportion of non-current assets, indicating potential long-term stability and investment in fixed assets.

Edgewise Therapeutics Inc Non-current Assets to Total Assets Ratio for the year ending December 31, 2022 was 0.04, a 164.95% change year over year.
Edgewise Therapeutics Inc Non-current Assets to Total Assets Ratio for the year ending December 31, 2021 was 0.02, a 37.03% change year over year.
Edgewise Therapeutics Inc Non-current Assets to Total Assets Ratio for the year ending December 31, 2020 was 0.01, a -43.97% change year over year.
Edgewise Therapeutics Inc Non-current Assets to Total Assets Ratio for the year ending December 31, 2019 was 0.02.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends